20 Oct 2022

Director/PDMR Shareholding

Investors

20 Oct 2022

Admission of the Company’s Ordinary Shares

Investors

20 Oct 2022

Posting of the Company’s Open Offer Circular

Investors

18 Oct 2022

Result of placing

Investors

18 Oct 2022

Proposed placing, open offer and issue of convertible bonds

Diagnostics | Investors

18 Oct 2022

Proposed acquisition of Launch Diagnostics

Diagnostics | Investors

29 Sep 2022

Interim Results for the Period Ended 30 June 2022

Investors

26 Sep 2022

Notice of Results

Investors

05 Sep 2022

AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration

Investors | Therapeutics

01 Sep 2022

Phase I clinical study of AVA6000 to advance to the fourth cohort

Investors | Therapeutics